CN109395077A - 211 biological immunes gram poison technology - Google Patents
211 biological immunes gram poison technology Download PDFInfo
- Publication number
- CN109395077A CN109395077A CN201811278500.6A CN201811278500A CN109395077A CN 109395077 A CN109395077 A CN 109395077A CN 201811278500 A CN201811278500 A CN 201811278500A CN 109395077 A CN109395077 A CN 109395077A
- Authority
- CN
- China
- Prior art keywords
- nano
- magnetic powder
- heat
- venereal disease
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
The invention belongs to biological agent technical fields, and the invention discloses the malicious technologies of 211 biological immunes gram, including composition；The composition includes nano target medicine for magnetothermal therapy and heat-resisting protective antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；The effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is 1:0.0007-0.17；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；The weight ratio of venereal disease antigen vaccine and heat resisting protective is 0.5-0.8:0.6-1.5；The preparation method includes A, prepares nano target medicine for magnetothermal therapy: the nano target medicine for magnetothermal therapy injection with target function is made by coupling in nano-magnetic powder；B, it prepares heat-resisting protective antigen-drug: heat-resisting protective antigen-drug injection being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion.
Description
Technical field
The invention belongs to biological agent technical fields, and in particular to 211 biological immunes gram poison technology.
Background technique
Venereal disease (venereal disease) traditional concept refers to that the disease infected by sex act, major lesions occur
In genital area.Including HPV (human papilloma virus), condyloma and bleb.Venereal disease is worldwide pandemic one
Group common transmittable disease, and the trend that Epidemic Scope expands, age of onset reduces, antibody-resistant bacterium increases, especially AIDS is presented
Be significantly increased, it has also become serious public health problem.The preventing and controlling of venereal disease will be one very arduous and long-term appoint
Business.
Venereal disease is the general name of one group of disease, and symptom is different because of disease, and after having infected sexual reverse, somebody has significantly
Clinical manifestation, but somebody does not have any performance yet.Human papilloma virus (HPV) is a kind of cream for belonging to papovaviridae
Head tumor vacuolating virus A belongs to, and is spherical DNA virus, the scaly epithelium of human skin mucous membrane can be caused to be proliferated.Show as HPV (human milk
Head tumor virus), the symptoms such as condyloma and bleb.And for HPV (human papilloma virus), condyloma and bleb, existing therapeutic agent,
Effect is poor, it is more difficult to cure.
Summary of the invention
In order to solve the above problems existing in the present technology, it is an object of that present invention to provide the malicious technologies of 211 biological immunes gram.
The technical scheme adopted by the invention is as follows:
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.0007-0.17；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and
The weight ratio of heat resisting protective is 0.5-0.8:0.6-1.5.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 2 parts -4 parts of trehalose, glucose
6-9 parts, 0.45 part -1.8 parts of gelatin, 2.1 parts -3.9 parts of thiocarbamide, 3-6.5 parts and water 80-90 parts of PVP K30.
Further, the nano-magnetic powder is super-paramagnetism nano magnetic powder；The grain diameter of the nano-magnetic powder is 25-
29nm。
Further, the nano-magnetic powder is the modified Nano magnetic powder by surface modification or modification；The modified Nano
Magnetic powder is made of surface modifier and nano-magnetic powder；The weight ratio of the nano-magnetic powder and surface modifier is 0.6-0.8:
0.0007-0.15。
Further, the surface modifier is n-capric acid, polyethylene glycol, glucan, nucleotide or polypeptide.
Further, the venereal disease antibody and venereal disease vaccine are respectively the venereal disease antibody and property of same type of sex desease virus
Disease vaccine；The venereal disease antibody is HPV antibody, condyloma antibody or bleb antibody；The venereal disease antigen vaccine is HPV antigen epidemic disease
Seedling, condyloma antigen vaccine or herpes antigen vaccine.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
The invention has the benefit that the malicious technology of 211 biological immunes gram of the invention, passes through magnetic thermotherapy nano target medicine
Object and heat-resisting protective antigen-drug are divided into antibody drug and antigen-drug is applied in combination, and the use for first passing through antigen-drug makes patient
The quantity of intracorporal antibody is quickly increased；Then through disease sites are acted on by antibody drug and eliminates virion, it should
Method increases the antibody of patient's body quickly, shortens the course of disease period, and enhance antibody by using nano-magnetic powder
Function and effect, improve the storage stability of venereal disease original vaccine further through heat resisting protective so that the two treatment when,
It is applied in combination with preferable therapeutic effect；In addition, the present invention can be in human body using composition made of the biological immune factor
Portion forms immune response, forms extended protection net, and after treatment effect prevents the secondary invasion of virus, and complete treatment prevents multiple
Hair.
Specific embodiment
Further explaination is done to the present invention combined with specific embodiments below.
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.0007-0.17；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and
The weight ratio of heat resisting protective is 0.5-0.8:0.6-1.5.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 2 parts -4 parts of trehalose, glucose
6-9 parts, 0.45 part -1.8 parts of gelatin, 2.1 parts -3.9 parts of thiocarbamide, 3-6.5 parts and water 80-90 parts of PVP K30.
Further, the nano-magnetic powder is super-paramagnetism nano magnetic powder；The grain diameter of the nano-magnetic powder is 25-
29nm。
Further, the nano-magnetic powder is the modified Nano magnetic powder by surface modification or modification；The modified Nano
Magnetic powder is made of surface modifier and nano-magnetic powder；The weight ratio of the nano-magnetic powder and surface modifier is 0.6-0.8:
0.0007-0.15。
Further, the surface modifier is n-capric acid, polyethylene glycol, glucan, nucleotide or polypeptide.
Further, the venereal disease antibody and venereal disease vaccine are respectively the venereal disease antibody and property of same type of sex desease virus
Disease vaccine；The venereal disease antibody is HPV antibody, condyloma antibody or bleb antibody；The venereal disease antigen vaccine is HPV antigen epidemic disease
Seedling, condyloma antigen vaccine or herpes antigen vaccine.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 1
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.0007；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting
Protectant weight ratio is 0.5:0.6.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 2 parts of trehalose, 6 parts of glucose,
0.45 part of gelatin, 3.9 parts of thiocarbamide, 3 parts and 80 parts of water of PVP K30.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 2
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.17；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting guarantor
The weight ratio for protecting agent is 0.8:1.5.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 4 parts of trehalose, 9 parts of glucose,
1.8 parts of gelatin, 2.1 parts of thiocarbamide, 6.5 parts and 90 parts of water of PVP K30.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 3
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.1；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting protective
The weight ratio of agent is 0.6:1.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 3 parts of trehalose, 8 parts of glucose,
1 part of gelatin, 3 parts of thiocarbamide, 4 parts and 86 parts of water of PVP K30.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 4
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.05；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting guarantor
The weight ratio for protecting agent is 0.9.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 2 parts of trehalose, 8 parts of glucose,
0.9 part of gelatin, 2.8 parts of thiocarbamide, 4 parts and 86 parts of water of PVP K30.
Further, the nano-magnetic powder is super-paramagnetism nano magnetic powder；The grain diameter of the nano-magnetic powder is 25nm.
Further, the nano-magnetic powder is the modified Nano magnetic powder by surface modification or modification；The modified Nano
Magnetic powder is made of surface modifier and nano-magnetic powder；The weight ratio of the nano-magnetic powder and surface modifier is 0.7:0.05.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 5
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.008；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting guarantor
The weight ratio for protecting agent is 0.55:0.78.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 2.1 parts of trehalose, glucose 6.2
Part, 0.83 part of gelatin, 2.6 parts of thiocarbamide, 4.2 parts and 82 parts of water of PVP K30.
Further, the nano-magnetic powder is super-paramagnetism nano magnetic powder；The grain diameter of the nano-magnetic powder is 29nm.
Further, the nano-magnetic powder is the modified Nano magnetic powder by surface modification or modification；The modified Nano
Magnetic powder is made of surface modifier and nano-magnetic powder；The weight ratio of the nano-magnetic powder and surface modifier is 0.69:0.095.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 6
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.06；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting guarantor
The weight ratio for protecting agent is 0.67:0.88.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 3.5 parts of trehalose, glucose 7.9
Part, 1.2 parts of gelatin, 3.3 parts of thiocarbamide, 6.2 parts and 87 parts of water of PVP K30.
Further, the nano-magnetic powder is super-paramagnetism nano magnetic powder；The grain diameter of the nano-magnetic powder is 27nm.
Further, the nano-magnetic powder is the modified Nano magnetic powder by surface modification or modification；The modified Nano
Magnetic powder is made of surface modifier and nano-magnetic powder；The weight ratio of the nano-magnetic powder and surface modifier is 0.66:0.009.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 7
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.08；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting guarantor
The weight ratio for protecting agent is 0.7:1.1.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 3 parts of trehalose, glucose 7.1
Part, 1.3 parts of gelatin, 3.6 parts of thiocarbamide, 5.8 parts and 89 parts of water of PVP K30.
Further, the nano-magnetic powder is super-paramagnetism nano magnetic powder；The grain diameter of the nano-magnetic powder is 26nm.
Further, the nano-magnetic powder is the modified Nano magnetic powder by surface modification or modification；The modified Nano
Magnetic powder is made of surface modifier and nano-magnetic powder；The weight ratio of the nano-magnetic powder and surface modifier is 0.79:0.04.
Further, the surface modifier is n-capric acid, polyethylene glycol, glucan, nucleotide or polypeptide.
Further, the venereal disease antibody and venereal disease vaccine are respectively the venereal disease antibody and property of same type of sex desease virus
Disease vaccine；The venereal disease antibody is HPV antibody, condyloma antibody or bleb antibody；The venereal disease antigen vaccine is HPV antigen epidemic disease
Seedling, condyloma antigen vaccine or herpes antigen vaccine.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 8
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.15；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting guarantor
The weight ratio for protecting agent is 0.69:0.9.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 2.9 parts of trehalose, glucose 6.9
Part, 0.9 part of gelatin, 2.9 parts of thiocarbamide, 3.8 parts and 84 parts of water of PVP K30.
Further, the nano-magnetic powder is super-paramagnetism nano magnetic powder；The grain diameter of the nano-magnetic powder is 27nm.
Further, the nano-magnetic powder is the modified Nano magnetic powder by surface modification or modification；The modified Nano
Magnetic powder is made of surface modifier and nano-magnetic powder；The weight ratio of the nano-magnetic powder and surface modifier is 0.77:0.075.
Further, the surface modifier is n-capric acid, polyethylene glycol, glucan, nucleotide or polypeptide.
Further, the venereal disease antibody and venereal disease vaccine are respectively the venereal disease antibody and property of same type of sex desease virus
Disease vaccine；The venereal disease antibody is HPV antibody, condyloma antibody or bleb antibody；The venereal disease antigen vaccine is HPV antigen epidemic disease
Seedling, condyloma antigen vaccine or herpes antigen vaccine.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
Embodiment 9
211 biological immunes gram poison technology, including composition；Composition includes nano target medicine for magnetothermal therapy and heat-resisting guarantor
Protect antigen-drug；The nano target medicine for magnetothermal therapy is made up of effector molecule and guide molecule of solution coupling；It is described
Effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight proportion of the nano-magnetic powder and venereal disease antibody is
1:0.02；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease antigen vaccine and heat-resisting guarantor
The weight ratio for protecting agent is 0.73:0.74.
Further, the heat resisting protective is grouped as by the group of following parts by weight: 3 parts of trehalose, glucose 6.2
Part, 1.2 parts of gelatin, 3.1 parts of thiocarbamide, 4.5 parts and 82 parts of water of PVP K30.
Further, the nano-magnetic powder is super-paramagnetism nano magnetic powder；The grain diameter of the nano-magnetic powder is 28nm.
Further, the nano-magnetic powder is the modified Nano magnetic powder by surface modification or modification；The modified Nano
Magnetic powder is made of surface modifier and nano-magnetic powder；The weight ratio of the nano-magnetic powder and surface modifier is 0.72:0.8.
Further, the surface modifier is n-capric acid, polyethylene glycol, glucan, nucleotide or polypeptide.
Further, the venereal disease antibody and venereal disease vaccine are respectively the venereal disease antibody and property of same type of sex desease virus
Disease vaccine；The venereal disease antibody is HPV antibody, condyloma antibody or bleb antibody；The venereal disease antigen vaccine is HPV antigen epidemic disease
Seedling, condyloma antigen vaccine or herpes antigen vaccine.
The preparation method of 211 biological immunes gram poison technology, comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: the magnetic thermotherapy with target function is made by coupling in nano-magnetic powder
With nano target medicine injection；
B, it prepares heat-resisting protective antigen-drug: being made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion heat-resisting
Protect antigen-drug injection.
The present invention is not limited to above-mentioned optional embodiment, anyone can show that other are each under the inspiration of the present invention
The product of kind form.Above-mentioned specific embodiment should not be understood the limitation of pairs of protection scope of the present invention, protection of the invention
Range should be subject to be defined in claims, and specification can be used for interpreting the claims.
Claims (7)
1.211 biological immunes gram poison technology, it is characterised in that: including composition；Composition includes magnetic thermotherapy nano target medicine
Object and heat-resisting protective antigen-drug；The nano target medicine for magnetothermal therapy is coupled by effector molecule and guide molecule by solution
It is made；The effector molecule is nano-magnetic powder, and the guide molecule is venereal disease antibody；The weight of the nano-magnetic powder and venereal disease antibody
Amount proportion is 1:0.0007-0.17；The heat-resisting protective antigen-drug includes venereal disease antigen vaccine and heat resisting protective；Venereal disease is anti-
The weight ratio of former vaccine and heat resisting protective is 0.5-0.8:0.6-1.5.
2. the malicious technology of 211 biological immune gram according to claim 1, it is characterised in that: the heat resisting protective is by as follows
The group of parts by weight is grouped as: 2 parts -4 parts of trehalose, 6-9 parts of glucose, 0.45 part -1.8 parts of gelatin, 2.1 part -3.9 of thiocarbamide
Part, 3-6.5 parts and water 80-90 parts of PVP K30.
3. the malicious technology of 211 biological immune gram according to claim 1, it is characterised in that: the nano-magnetic powder is superparamagnetic
Property nano-magnetic powder；The grain diameter of the nano-magnetic powder is 25-29nm.
4. the malicious technology of 211 biological immune gram according to claim 1, it is characterised in that: the nano-magnetic powder is by table
The modified Nano magnetic powder of face modification or modification；The modified Nano magnetic powder is made of surface modifier and nano-magnetic powder；It is described to receive
The weight ratio of rice magnetic powder and surface modifier is 0.6-0.8:0.0007-0.15.
5. the malicious technology of 211 biological immune gram according to claim 1, it is characterised in that: the surface modifier is positive the last of the ten Heavenly stems
Acid, polyethylene glycol, glucan, nucleotide or polypeptide.
6. the malicious technology of 211 biological immune gram according to claim 1, it is characterised in that: the venereal disease antibody and venereal disease epidemic disease
Seedling is respectively the venereal disease antibody and venereal disease vaccine of same type of sex desease virus；The venereal disease antibody is HPV antibody, condyloma antibody
Or bleb antibody；The venereal disease antigen vaccine is HPV antigen vaccine, condyloma antigen vaccine or herpes antigen vaccine.
7. a kind of preparation method of the malicious technology of 211 biological immune gram as claimed in any one of claims 1 to 6, it is characterised in that:
Comprising steps of
A, it prepares nano target medicine for magnetothermal therapy: magnetic thermotherapy with target function is made with receiving by coupling in nano-magnetic powder
Rice targeted drug injection；
B, it prepares heat-resisting protective antigen-drug: heat-resisting protective is made after venereal disease antigen vaccine and heat resisting protective are mixed in proportion
Antigen-drug injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811278500.6A CN109395077A (en) | 2018-10-30 | 2018-10-30 | 211 biological immunes gram poison technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811278500.6A CN109395077A (en) | 2018-10-30 | 2018-10-30 | 211 biological immunes gram poison technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109395077A true CN109395077A (en) | 2019-03-01 |
Family
ID=65470345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811278500.6A Pending CN109395077A (en) | 2018-10-30 | 2018-10-30 | 211 biological immunes gram poison technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109395077A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772303A (en) * | 2005-10-25 | 2006-05-17 | 朱宏 | Nanometer magnetic powder-antibody targeting medicine for magneto thermical threrapy of malignant tumor |
| CN1785430A (en) * | 2005-10-25 | 2006-06-14 | 南京工业大学 | Nano-magnetic powder antihuman lirer cancer single anti HAb18 target medicine for magnetic heat therapy |
| CN1951495A (en) * | 2005-10-25 | 2007-04-25 | 朱宏 | Nano target medicine for magnetothermal therapy of malignant tumor |
| CN106729731A (en) * | 2016-12-14 | 2017-05-31 | 四川省华派生物制药有限公司 | A kind of preparation method of vaccine heat resisting protective, vaccine and vaccine |
| CN107949397A (en) * | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | Immunization therapy vaccine and Antibody Combination treatment |
-
2018
- 2018-10-30 CN CN201811278500.6A patent/CN109395077A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772303A (en) * | 2005-10-25 | 2006-05-17 | 朱宏 | Nanometer magnetic powder-antibody targeting medicine for magneto thermical threrapy of malignant tumor |
| CN1785430A (en) * | 2005-10-25 | 2006-06-14 | 南京工业大学 | Nano-magnetic powder antihuman lirer cancer single anti HAb18 target medicine for magnetic heat therapy |
| CN1951495A (en) * | 2005-10-25 | 2007-04-25 | 朱宏 | Nano target medicine for magnetothermal therapy of malignant tumor |
| CN107949397A (en) * | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | Immunization therapy vaccine and Antibody Combination treatment |
| CN106729731A (en) * | 2016-12-14 | 2017-05-31 | 四川省华派生物制药有限公司 | A kind of preparation method of vaccine heat resisting protective, vaccine and vaccine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Orford et al. | Bleomycin therapy for cystic hygroma | |
| CN105031625B (en) | Lactoferrin and carragheen composition of medicine of a kind of electric charge modification and preparation method thereof | |
| CN111012896A (en) | Functional dressing for preventing and controlling human papilloma virus infection and preparation method thereof | |
| JP4854742B2 (en) | Use of Nocardia rubra cell wall skeleton in the preparation of anti-HPV infection drugs | |
| CN109395077A (en) | 211 biological immunes gram poison technology | |
| EP2094300B1 (en) | Medicinal formulation for the treatment for hepatitis c | |
| US20210196676A1 (en) | Treatment of viral infections and virally associated lesions with sequiterpene lactones | |
| CN105597092A (en) | Interleukin 15-containing vaccine spraying agent for preventing and treating HPV infection | |
| EP2327420A2 (en) | Monoparaimmunity inducers based on attenuated rabbit myxoma viruses | |
| AU2022204563A1 (en) | Application and method of superoxide dismutase in preparing medicine for treating psoriasis | |
| Al-Azmi et al. | Human papillomavirus: manifestations, prevention and treatment: an overview | |
| WO2019144874A1 (en) | Application of zikv attenuated strain in treatment of brain glioma | |
| CN101987125A (en) | Medicine for treating verruca plana and preparation method thereof | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN103071098A (en) | Ointment for treating foot warts and application thereof | |
| CN106267167A (en) | A kind of lactalbumin oleic acid complex and carrageenan composition of medicine and its preparation method and application | |
| Rosales | Strategies for Developing A Cervical Cancer Vaccine | |
| Yevheniia et al. | HOW COVID-19 PANDEMIC GAVE IMPETUS TO THE DEVELOPMENT OF HIV VACCINES | |
| Ismael et al. | Immunotherapy Growing Role in Warts Management | |
| Mangla et al. | COVID-19: A Significant Revival Approach-Concurrent Case Study in India | |
| Prens | Condylomas inside and outside, to treat or not to treat | |
| CN112891519A (en) | Polypeptide anti-HPV pharmaceutical composition, preparation method and application thereof | |
| US20210308080A1 (en) | Transient induced systemic acidosis (tisa) to treat virus infections | |
| Stephen et al. | Viruses as part of biological diversity and some examples of most dangerous ones (HIV/AIDS and zika virus) | |
| Protasov et al. | Anogenital Warts: New Opportunities for Prevention and Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190301 |
|
| RJ01 | Rejection of invention patent application after publication |